Rehmapicrogenin attenuates lipopolysaccharide‐induced podocyte injury and kidney dysfunctions by regulating nuclear factor E2‐related factor 2/antioxidant response element signalling

Abstract

AbstractBackgroundApoptosis and oxidative stress in kidneys are critical players in acute kidney injury (AKI). Rehmapicrogenin, a monomeric compound extracted from Rehmanniae radix, has been found to possess nitric oxide inhibitory and anti‐inflammatory activities. Thus, this study aimed to investigate the roles and mechanisms of rehmapicrogenin in AKI.MethodsLipopolysaccharide (LPS) was used to induce AKI‐like conditions. Cell survival conditions were detected by cell counting kit‐8 assays and flow cytometry. Several renal function markers including blood urea nitrogen, proteinuria, creatinine, and albumin were measured. Apoptosis and reactive oxygen species (ROS) production were examined by TUNEL and dihydroethidium staining, respectively. Haematoxylin–eosin staining and periodic acid‐Schiff staining were conducted to assess histopathological changes. Gene expression was evaluated by western blotting, commercially available kits and immunofluorescence staining.ResultsFor in vitro analysis, rehmapicrogenin inhibited the LPS‐induced podocyte apoptosis by activating the Nrf2/ARE pathway. For in vivo analysis, rehmapicrogenin improved renal functions in LPS‐induced mice. Additionally, rehmapicrogenin suppressed LPS‐induced podocyte apoptosis and oxidative stress in kidney tissues. Mechanistically, rehmapicrogenin activated the Nrf2/ARE pathway in LPS‐induced mice.ConclusionRehmapicrogenin relieves the podocyte injury and renal dysfunctions through activating the Nrf2/ARE pathway to inhibit apoptosis and oxidative stress.image